Weber Christophe Pierre 4

What Happened Christophe Weber, a director of Boston Scientific Corporation (BSX), received equity awards on 2026-05-07 totaling 5,567 shares/units: 1,767 restricted shares (award), 1,140 restricted shares (award), and 2,660 deferred stock units (derivative award). All awards are reported at $0.00 per share because they were grants (not open-market purchases) and together reflect an approximate aggregate value of $315,000 based on the company’s stated valuations.

Key Details

• Transaction date: 2026-05-07; Filing date: 2026-05-11 (filed 4 days after the transaction, which is longer than the standard two-business-day Form 4 deadline).
• Reported transaction codes: A = Award/Grant (no cash purchase or sale).
• Share counts: 1,767 RSUs (F1), 1,140 RSUs (F2), 2,660 deferred stock units (F3/F4) — total 5,567.
• Price reported: $0.00 per share (awards/grants).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Notable footnotes:
  • F1: 1,767 restricted shares granted in lieu of 80% of annual cash retainer (~$100,000).
  • F2: 1,140 restricted shares from 30% portion of the annual equity award (~$64,500).
  • F3/F4: 2,660 deferred stock units (each represents one share to be issued later); F4 notes these units vest at the next annual meeting and will be issued following separation from board service. The deferred portion reflects ~$150,500 (70% of the $215,000 annual equity award).
• Filing timeliness: The filing appears to have been submitted later than the typical two-business-day requirement.

Context These entries are compensation awards for a non-employee director (part of the director compensation program) and are not open-market purchases or sales; they do not by themselves indicate personal buying/selling sentiment. The deferred stock units are a promise to issue shares later (per the company’s Deferred Compensation Plan) and are treated as derivative awards until converted.